Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...

On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...

Bristol Myers Squibb shares rose Friday, a day after its schizophrenia drug was approved for use by the Food and Drug Administration.

Terence Flynn, an analyst from Morgan Stanley, maintained the Sell rating on Bristol-Myers Squibb (BMY – Research Report). The associated ...

After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...

Analyst Chris Shibutani from Goldman Sachs reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report) and keeping the price ...

Bristol-Myers Squibb's acquisition of Karuna for $14bn and the subsequent FDA approval of Cobenfy, a novel schizophrenia drug, represents a significant strategic win. Cobenfy, the first new ...

Shares of pharmaceutical company Bristol Myers Squibb ($BMY) are up 4% on news that the U.S. Food and Drug Administration ...